Our December speaker is Dr. Elizabeth Garner, a functional genomics scientist at Caribou Biosciences, Inc.
Dr. Garner will discuss Caribou Biosciences’ approaches toward “Understanding CRISPR-Cas9 Activity to Enable Industrial Applications of Gene Editing” and will explore the ways in which Caribou Biosciences has been working on understanding CRISPR-Cas9 technology and its use in diverse fields of biotechnology.
Caribou Biosciences, Inc. is a leading company in CRISPR genome engineering located in Berkeley, CA, winner of the 2016 East Bay Innovation Awards in Life Sciences. Caribou Biosciences is pioneering the translation of CRISPR-Cas genome engineering into new medical therapies and bio-based products.
The Caribou Biosciences genome editing technology platform is centered on Cas9, a protein derived from the CRISPR-Cas prokaryotic immune system. Cas9 is a programmable nuclease that acts as a type of molecular scissors. Cas9 uses short RNA molecules, known as guide RNAs, to target the protein to a specific sequence within cellular DNA. By changing the sequence of the guide RNA, Cas9 can be directed to almost any DNA sequence, enabling simple and flexible targeting of nearly any site in a given genome. The Caribou Biosciences CRISPR-Cas technology platform has the potential to revolutionize the future of therapeutics, agriculture, biological research, and industrial biotechnology.
Join colleagues at our Aquatic Park Center campus in Berkeley for this latest luncheon series, co-hosted by Lawrence Berkeley National Laboratory and QB3 East Bay Innovation Center. Be our guest for a brown bag lunch.
Event registration is mandatory for admission. Please know that parking is limited. We advise that you walk, bike or take the Emery-Go-Round. EGR lets you out at 2929 Seventh Street, a two-block walk to 717 Potter Street. Thank you!
Follow us on Twitter @WarehamProperty.